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Hepatitis B related active hepatitis is more in-
dolent and treatment is not so urgent. If the patient 
is hepatitis e antigen positive, corticosteroids 
should on no account be given as they increase 
virus replication. Treatment with antiviral drugs 
such as interferons must be considered, but their 
position has not been established and they are not 
generally available. If the patient is hepatitis e 
antigen negative, a trial of prednisolone may be 
considered, but if clinical and biochemical im-
provement has not followed three months' ther-
apy, it should be stopped. 
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Biliary Atresia, Biliary Hypoplasia, and Arter-
iohepatic Dysplasia (Alagilles Syndrome). Extra-
hepatic biliary atresia is responsible for approxi-
mately one-third of the cases of neonatal cholestatic 
jaundice. In 10% of biliary atresias, the lesion is 
either a distal atresia with patent proximal hepatic 
ducts or a cystic dilatation of ducts adjacent to the 
hilum of the liver. In these correctable forms of 
biliary atresia, reconstruction can be achieved by 
anastomosis of the patent extrahepatic bile duct 
or the gallbladder to a Roux-en-Y jejunostomy. 
Prognosis is excellent after biliary reconstruction. 
In more common, noncorrectable forms of bil-
iary atresia, there are no patent extrahepatic ducts, 
and the gallbladder is absent or rudimentary. For 
these lesions, hepatic portoenterostomy (Kasai op-
eration) has been tried with varying degrees of 
success. Successful bile flow may be established in 
nearly all patients when the intrahepatic bile ducts 
at the hilum are· greater than 150 j..L in diameter 
but in only one-tenth of patients in whom such 
ducts are not demonstrable. In addition, the sur-
gical success rate is related to the timing of oper-
ation. Success rales of 80-90o/c are reported if 
surgery is performed before 2 months of life, but 
the success rate falls to 20% after 3 months. It is 
deceptive to define success in terms of bile flow, 
since only 25% of patients are alive and free of 
jaundice 1-6 years after operation. 
Cholangitis is a major problem after hepatic 
portoenterostomy. Prophylactic use of oral anti-
biotics, such as trimethoprim-sulfamethoxazole 
and cephradine, for a year has been advocated to 
suppress recurrent cholangitis. Various types of 
cutaneous enterostomy and complicated enteroen-
terostomy have been devised to reduce the risk of 
cholangitis, but none has been proved to be su-
perior to a simple Roux-en-Y jejunostomy. Bleed-
ing at or near the mucocutaneous junction is a 
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common and serious complication of stomas that 
are left in place in the late stage of biliary atresia. 
Revision of hepatic porto enterostomy should be 
limited to patients who became jaundice-free after 
an initial Kasai operation and who later develop 
recurrent jaundice due to obstruction or to a 
patient whose operation is judged to have been 
inadequate after review of previous medical rec-
ords and pathology specimens. 
Liver transplantation has become an alternative 
treatment of biliary atresia in the last several years. 
Before 1980, I-year survival after liver transplan-
tation for biliary atresia was 25% using conven-
tional immunosuppressive therapy (azathioprine, 
prednisone, and antilymphocyte globulin). Since 
early 1980, I-year survival has increased to 75%. 
Improvement has been due to better immuno-
suppression with cyclosporine and low doses of 
steroids. Five-year survival is projected at more 
than 50%. 
Almost all recipients with biliary atresia have 
had earlier attempts at hepatic portoenterostomy. 
The I-year survival rate of patients with biliary 
atresia is 20% less than that of patients with liver-
based inborn metabolic errors, such as alpha!-
antitrypsin deficiency, tyrosinemia, and Wilson's 
disease. The previous hepatic portoenterostomy, 
which made the transplantation operation ex-
tremely difficult in many patients, has been re-
sponsible for the poorer outlook. Revisions and 
re-revisions of hepatic portoenterostomy, the 
placement of cutaneous enterostomy stomas, and 
the use of complicated enteric anastomoses other 
than simple Roux-en-Y jejunostomy are all adverse 
factors if liver transplantation is finally needed. 
Although some authors advocate aggressive sur-
gical therapy for biliary hypoplasia, hepatic por-
toenterostomy cannot be recommended. It is not 
only ineffective, but it also causes recurrent cho-
langitis. Arteriohepatic dysplasia (Alagilles syn-
drome) can be diagnosed by the characteristic 
features of broad forehead, deeply set and widely 
spread eyes, pointed chin, vertebral arch defects, 
pulmonary artery stenosis, and cholestatic jaundice 
due to a paucity of intralobular ducts. Both biliary 
hypoplasia and arteriohepatic dysplasia are good 
indications for liver transplantation. 
Nutritional support is essential for children with 
these diseases to maintain their development. Vi-
tamins, particularly A, D, and E, and calcium' 
should be supplemented. Nutritional support con-
sists of a diet high in proteins and low in fats. 
Formula with medium-chain triglycerides is now 
available. 
Choledochal Cyst. In the past, choledochal cysts 
were drained by choledochocyst-duodenostomy or 
choledochocyst-jejunostomy in Roux-en-Y. The 
majority of patients so treated became relatively 
asymptomatic for a number of years after the 
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. internal drainage operation, but many developed 
delayed complications, such as recurrent cholan-
gitis, formation of biliary calculi, and progressive 
hepatic fibrosis. The development of malignant 
disease within the choledochal cysts or elsewhere 
in the biliary duct system has been reported re-
peatedly. The incidence of this complication is 
approximately 5%. 
As a consequence of these complications and 
their increasing recognition, more and more sur-
geons are advising partial or complete excision of 
the cysts with performance of a Roux-en-Y jejunal 
anastomosis to the relatively normal proximal end 
of the duct system. If a part of the cyst wall cannot 
be resected because of technical difficulties, the 
mucosa lining should be stripped. 
Caroli's Disease. Congenital segmental dilata-
tion of the intrahepatic biliary duct system is called 
Caroli's disease. This disease is occasionally asso-
ciated with congenital hepatic fibrosis, cystic spon-
giosis of the renal medulla, and cystic disease of 
the pancreas. 
The large intrahepatic ducts of both lobes of 
the liver are usually involved. If the right and left 
main intrahepatic ducts are dilated at the hilum, 
a large hepaticojejunostomy in Roux-en-Y will 
relieve bile stasis, thereby reducing the chance of 
cholangitis and stone formation. If many biliary 
stones have already formed, the tip of the jejunal 
Raux loop is brought up to the skin to create the 
jejunal stoma. Through this stoma, the retained 
stones can be removed postoperatively by endo-
scopic or radiologic maneuvers. 
Rarely, the cystic dilations are confined to one 
lobe of the liver. Hepatic resection is indicated 
only in these unusual circumstances. 
Cholecystitis and Cholelithiasis. Cholelithiasis 
in children is usually a complication of hemolytic 
diseases, such as hereditary spherocytosis, sickle 
cell disease, and thalassemia major. Adult types of 
cholesterol stones are occasionally seen in post-
pubertal children. Children with cholelithiasis 
should undergo elective cholecystectomy in the 
same way as adults. If the cholelithiasis is compli-
cated by acute cholecystitis, the child should be 
treated with antibiotics first. If the signs of acute 
inflammation subside with antibiotic therapy, the 
cholecystectomy is performed electively during the 
same hospitalization, but if there is not a good 
response within 48-72 hours, emergency chole-
cvstectomv is carried out. 
, Acalcul~us cholecystitis may occur in children 
during acute febrile 'illnesses, severe diarrhea, and 
postoperative convalescence. or it mav follow 
major trauma and large burns. These patients are 
ordinarily treated by intensive antibiotic therapy 
and gastric suction. However, if gallbladder dis-
tension is progressive, cholecystectomy is per-
formed. If recovery from the acute illness is com-
plete, residual gallbladder disease is not apparent. 
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ACUTE PANCREATITIS 
The general principles of treatment of acute 
pancreatitis are (1) to treat hypovolemia and elec-
trolyte abnormalities, (2) to relieve pain, (3) to 
reduce pancreatic secretions, and (4) to remove 
the precipitating cause. 
Correction of hypovolemia should begin im-
mediately, utilizing a large-bore central venous 
catheter for fluid replacement and to monitor 
central venous pressure. Hypotension and low 
central venous pressure should be corrected as 
rapidly as possible with plasma, dextran, albumin, 
or whole blood. Shock is the main cause of death 
in acute pancreatitis. Shock is primarily a result of 
exudation of plasma into the retroperitoneal space 
and peripheral vasodilatation caused by increased 
kinin activity. 
After hypovolemia has been corrected, the rate 
of intravenous infusions should be reduced so as 
to provide maintenance plus replacement of on-
going losses from nasogastric suctioning and ex-
udation into the peritoneal and retroperitoneal 
spaces. Monitoring urine output and central ye-
nous pressure are mechanisms for assessing the 
adequacy of the fluid replacement. Major compli-
cations of treatment of severe acute pancreatitis 
are pulmonary edema and congestive heart failure; 
these usually occur 3 to 7 days after the onset of 
pancreatitis. Though in many cases the cause is 
unknown, in some cases fluid overload has oc-
curred because of excessive fluid replacement. 
Thus, the amount of fluid replacement must be 
adjusted frequently for changes in intravascular 
volume. 
Serum electrolytes, including calcium and mag-
nesium, serum creatinine, and blood urea nitrogen 
determinations, will aid in selecting the appropri-
ate electrolyte composition of intravenous solu-
tions. Since between 2 and 17 per cent of patients 
with acute pancreatitis have renal failure, potas-
sium should not be added to IV solutions until 
stable urine output has been established. In addi-
tion to maintenance sodium chloride and potas-
sium chloride of 3 mEq/kg/24 hr and 2 mEq/kg! 
24 hI', respectively, losses from nasogastric suc-
tioning should be replaced. Though 5 per cent 
dextrose solutions should be initiated, hypergly-
cemia and hypoglycemia occasionally seen in se-
vere pancreatitis warrant careful monitoring of 
urinary reducing substances and blood glucose 
